stockrowCASI Pharmaceuticals Inc.
CASIF Healthcare Biotechnology
CASI Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.7 million, down 27.4% from fiscal 2024.
- Revenue
- −45.9%
- EPS
- +35.8%
- Free cash flow
- −23,251.7%
- Total debt
- +6.97%
Quarter to December 2025, against a year earlier
Follow CASIF
Alert me
CASI Pharmaceuticals Inc. (CASIF) EV/Sales
As of 6 November 2026, CASI Pharmaceuticals Inc. (CASIF) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from −0.6× (March 2023) to 319× (July 2018); the current reading is higher than 24% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.5× | 11.96% |
| FY2024 | 2.3× | (13.04%) |
| FY2023 | 2.6× | — |
| FY2022 | −0.5× | — |
| FY2021 | 2.1× | (87.79%) |
| FY2020 | 17.3× | (70.67%) |
| FY2019 | 58.8× | 323.78% |
| FY2015 | 13.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | 2.5× | 13.93% |
| Sep 2025 | 2.2× | 42.67% |
| Jun 2025 | 1.6× | (15.93%) |
| Mar 2025 | 1.9× | (18.07%) |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GUTS Fractyl Health, Inc. compare | −45.9× |
| TCRX TScan Therapeutics, Inc. compare | −6.2× |
| LPCN Lipocine Inc. compare | −1.5× |
| CASIF CASI Pharmaceuticals Inc. | 1.8× |
| BOLT Bolt Biotherapeutics, Inc. compare | 2.5× |
| DARE Dare Bioscience, Inc. compare | 3.9× |
| TVRD Tvardi Therapeutics, Inc. compare | 7.0× |
| BCDA BioCardia, Inc. compare | 28.7× |
| HIND Vyome Holdings, Inc. compare | 124× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)